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doi:10.1016/j.ejvs.2009.09.012Abstract Objective: Tocompare the costs involved (fromprocedure to recovery) following radio-
frequency ablation and conventional surgery for lower limb varicose veins in a selected population.
Design: Prospective randomised controlled trial.
Methods: Patients with symptomatic great saphenous varicose veins suitable for radiofrequency
ablationwere randomised to either RF ablation or surgery (sapheno-femoral ligation and stripping).
The hospital, general practice and patient costs incurred until full recovery and the indirect cost to
society, due to sickness leaveafter surgery,were calculated to indicatemean cost per patient under
each category.
Results: Ninety three patients were randomised. Eighty eight patients (47 e RF ablation, 41 e
surgery) underwent the allocated intervention. Ablation took longer to perform than surgery (mean
76.8vs47.0 min,p < .001).Ablationwasmoreexpensive (meanhospital costperpatient£1275.90vs
£559.13) but enabled patients to return to work 1 week earlier than after surgery (mean 12.2 vs
19.8 days, pZ 0.006). Based on the Annual Survey of Hours and Earnings (Office of National Statis-
tics, UK) for full time employees, the cost per working hour gained after ablation was £6.94 (95% CI
6.26, 7.62).
Conclusion: The increasedcostof radiofrequencyablation ispartlyoffsetbyaquicker return towork
in the employed group (ISRCTN29015169http://www.controlled-trials.com).
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.d at the 20th Annual Meeting
ary 20e23, 2008, Charleston,
im Lees, Freeman Hospital,
l.: þ44 191 213 7357/795 182
ail.com (S. Subramonia).
ty for Vascular Surgery. PublisheIntroduction
Varicose veins affecting the lower limb is a major health
problem in the Western World and often impairs the quality
of life (QOL).1,2 Surgical treatment, based on clinical
presentation and underlying pathophysiology, has beend by Elsevier Ltd. All rights reserved.
Table 1 Inclusion and exclusion criteria.
Inclusion criteria
 Age between 18 and 70 years, both sexes
 Duplex scan confirmed GSV incompetence (primary
or recurrent) requiring surgery
 Duplex scan confirmed suitability for RFA (see exclusion
criteria)
 Patient fit for a general anaesthetic
 Physical condition allowing ambulation after the
procedure
 Patient able to give informed consent
 Requirement for intervention agreed between patient and
the surgeon
 Availability of patients for all follow up visits
Exclusion criteria
 Varicose veins without GSV incompetence on duplex scan
 Associated short saphenous or deep venous incompetence
on duplex scan
 Tortuous GSV above the knee felt to be unsuitable for
catheterisation
 GSV diameter <3 mm or >12 mm in the supine position
 Thrombus in the GSV
 Patients with a pacemaker or internal defibrillator
 Concomitant peripheral arterial disease (ankle-brachial
pressure index of <0.9)
 Pregnancy
 Unable to complete QOL questionnaires due to poor
English language skills
Costs of Ablation and Surgery for Varicose Veins 105shown to improve QOL.1,3 Over 30,000 operations are
performed annually for varicose veins in England and Wales
at a considerable cost to the UK National Health Service
(NHS).4,5 The vast majority of these operations involve
sapheno-femoral ligation and stripping of the great saphe-
nous vein (GSV), inevitably followed by a variable period of
recovery that may last a few weeks. Surgery, even in the
absence of complications, may cause considerable early
morbidity and prolong recovery.6,7 This may have an impact
on productivity in a societal context. Varicose veins are
thus of clinical and economic importance to the NHS and
also have a significant socio-economic impact on society.
Recent years have seen the development of less
invasive, minimal access endovenous techniques of ablating
varicose veins with the potential to reduce postoperative
morbidity, facilitate quicker recovery and improve patient
satisfaction and treatment outcome. Radiofrequency
ablation (RFA) is one such method that uses radiofrequency
energy to achieve vein ablation in selected patients with
varicose veins due to superficial venous incompetence. Its
potential early benefits over conventional surgery (CS) have
now been confirmed by randomised controlled trials.8,9 Five
year outcomes after RFA are comparable to CS.10 Although
it is becoming increasingly popular it involves the use of
specialised equipment and is still perceived as a more
expensive alternative option to conventional surgery. This
is particularly so within a public healthcare system such as
the UK NHS where a tight financial budget may limit the
provision of a more expensive treatment option unless it is
proven to be overwhelmingly beneficial in a clinical
context. However the higher costs associated with RFA
could be offset against the benefit of a shorter recovery
period and this may have an impact on its future applica-
tion. Few studies have estimated the cost differences
between RFA and CS either in the short-term or in the long-
term.8 It is important that costs incurred with any new
treatment be accurately determined and balanced against
its potential benefits over established conventional
methods. This is best achieved by a comparison of the
outcomes between the treatments in a prospective rando-
mised controlled trial.
This paper reports the short-term costs incurred from
procedure to recovery between RFA and CS performed in
a selected population within a prospective randomised
controlled trial. The primary aim of the trial was to
compare the clinical outcome between the two procedures
with the primary outcome measure being the time taken to
return to full level of normal household activities. An
estimation of the involved treatment costs was performed
simultaneously and is the subject of this paper.Methods
The trial was carried out in the Vascular Surgical Unit of
a tertiary referral hospital. Approval was obtained from the
Local Research Ethics Committee. The inclusion and
exclusion criteria are summarised in Table 1. Over
12 months consecutive patients between 18 and 70 years
with symptomatic varicose veins (clinical, etiologic,
anatomic, pathophysiologic (CEAP) Clinical Class 2e6)
underwent clinical assessment and duplex ultrasonographyin a one-stop venous clinic. Patients with primary or
recurrent varicose veins due to isolated GSV incompetence
(i.e. no associated deep venous or short saphenous vein
incompetence) on duplex ultrasonography and suitable for
RFA were consented for participation in the trial and
allocated to receive either RFA or CS by a web-based
randomisation method. All operations were performed
under general anaesthetic. Patients randomised to RFA
received tumescent infiltration followed by ablation of the
GSV from just below the sapheno-femoral junction to the
level of the knee (VNUS Closure procedure, VNUS Medical
Technologies, Inc., San Jose, CA). Patients randomised to
CS underwent sapheno-femoral disconnection and stripping
of the GSV to the level of the knee. Both groups underwent
simultaneous phlebectomy of pre-operatively marked
varicosities using phlebectomy hooks. All RFA procedures
were performed by one Consultant Surgeon with over
3 years’ experience of this procedure.11 Either a Consultant
Surgeon or a Senior Registrar in Vascular Surgery was
actively involved in all the operations in the other arm (CS).
Patients were followed up towards the end of the first and
fifth weeks after their intervention. Costs related to
medical and nursing care during the postoperative period
were recorded at each hospital follow up along with other
outcome measures (morbidity, duration of recovery,
patient satisfaction, QOL, radiological) being evaluated in
the trial by an independent observer not involved in the
original operation. The details of any treatment or
consultation that was performed at the general practice or
patient’s home for any postoperative problem was also
recorded.
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NHS but general practice-related costs, patient-related
costs and indirect costs to society due to sickness leave
during the post-intervention period were also considered.
The emphasis was on estimating the difference in costs
between the two treatments. Thus protocol-driven costs
related to hospital visits, duplex ultrasound scans and
routine postoperative District Nurse home visits were
excluded from the final analysis as the number of events
was evenly matched in both groups. The costs incurred by
the hospital (Table 2), general practice (Table 3) and
patients were calculated to indicate the mean cost per
patient under each category. Estimation of theatre costs
was based on the recorded mean total time spent in theatre
(between entry into and exit from theatre suite) and the
number of operating staff normally present for both types
of operation being compared in this trial. Additional costs
for RFA resulted from the use of intraoperative duplex
ultrasound scan and the disposable ablation catheterTable 2 Costs incurred by the hospital per patient.a
Cost of the
operation (theatre
cost)
Scale (where
relevant)
Salary point
(where relevant)
Mean total theatre
time (min)
Surgeon
(Consultant)
MC72 08
Surgeon assistant
(SpR)
MN25 09
Anaesthetist
(Consultant)
MC72 08
Anaesthetic
assistant (ODA)
XR 61 Band 6 12
Scrub Nurse XR 61 Band 6 12
Floor Nurse XR 51 Band 5 12
Portering Band 2
Consumables
Staffing overheadb
Other Trust overheadc
Ablation catheter
Duplex scand
Theatre cost
Cost of day case ward
Cost of non-
protocol
outpatient visits
RFA e 2 visits for 47 patients
CS e 4 visits for 41 patients
Cost of non-
protocol duplex
ultrasound scans
RFA e none
CS e none
Mean hospital cost per patient
a Calculations based on 1 Consultant surgeon, 1 Specialist Registra
(operating department assistant), 1 Scrub nurse, 1 Floor nurse being
salary scale using 2005e2006 pay rates.
b Standard overhead based on overall costs e 3.3% of direct theatre
laundry).
c Standard Trust overhead based on overall costs e 30% of direct t
tration, etc.).
d Cost excludes cost of a technician as the scan was performed by(prevailing purchase price of £550.00 per catheter at the
time of the trial for Closure PLUS Intravascular catheter
(REF CL6-100, 6F or REF CL8-100, 8F supplied by VNUS
Medical Technologies Inc., San Jose, CA). The unit cost for
consultations with the general practitioner or practice
nurse and activities such as patient visits and District Nurse
home visits was obtained from standard sources.12 Patient
costs included the cost incurred by patients for undertaking
visits to their general practice or non-protocol hospital
follow up visits and the cost of purchase of antibiotics or
analgesics for any postoperative problem.
The indirect costs to society or loss of productivity from
being unable to work has been reported in previous
studies.8,13 The time taken to return to work following
treatment, the nature of employment and wages relevant
to the time of the trial were considered for this analysis.
Patients were asked whether, despite an uneventful
recovery, any operation-unrelated factor or factors had
delayed their return to work and whether they had takenQuantity Unit cost (£) RFA (£) CS (£)
83.6 55.7
1 61.90 per hour 86.25 57.46
1 30.02 per hour 41.83 27.87
1 61.90 per hour 86.25 57.46
1 22.30 per hour 31.07 20.70
1 22.30 per hour 31.07 20.70
1 17.78 per hour 24.77 16.51
1 5.36 per hour 4.97 4.97
1 50.00 50.00
1 3.3% 11.75 8.44
1 30.0% 106.86 76.70
1 550.00 550.00 0.00
1 37.00 37.00 0.00
1061.83 340.82
1 210.80 per day 210.80 210.80
77.00 per visit 3.28 7.51
60.00 per scan 0.00 0.00
1275.90 559.13
r (SpR) in Surgery, 1 Consultant anaesthetist, 1 Anaesthetic ODA
involved in each operation, with staff wage rates at maximum of
costs (includes sterile services, administration, domestic services,
heatre costs (includes estates, energy, capital charges, adminis-
the Surgeon.
Table 3 Costs incurred by general practice per patient.
Unit cost (£)a RFA CS
Total contacts Cost per
patient (£)
Total contacts Cost per
patient (£)
GPR
consultation
(10 min)
24.00 (2.40 per
minute)b
17 contacts
for 47 patients
8.68 24 contacts
for 41 patients
14.05
Practice nurse
consultation
10.00 per
consultationc
4 contacts
for 47 patients
0.85 18 contacts
for 41 patients
4.39
Non-protocol
District nurse
home visits
23.00 per home
visitd
None 0.00 3 contacts
for 41 patients
1.68
Mean general practice cost per patient 9.53 20.12
GPRZ General Practitioner.
a Unit costs of Health and Social Care 2005 (http://www.pssru.ac.uk/pdf/uc/uc2005/uc2005.pdf e last accessed 28 Apr 2009).
b Includes the cost of training and direct care support staff cost.
c Includes the cost of training.
d Includes the cost of training and travel costs.
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sickness leave to allow themselves an extended break from
work. Information regarding gross weekly earnings for
employees in the UK and the duration of weekly paid hours
of work was obtained from standard sources.14 A difference
of 7 days to return to work between the two treatments
was taken to indicate a difference of one working week (5
working days þ weekend).
Power calculation for the trial, based on an expected
clinically significant (75%) improvement in the primary
outcome (authors’ experience indicated that 40% of patients
returned to normal activities within a week following CS),
obtained a sample size of 84 patients, 42 in each arm (80%
power and significance level of 5%), with an additional 10%
to account for potential follow up loss. Analysis of costs was
based on the type of treatment received. Continuous
parametric data were analysed using Student’s t-test and
non-parametric data using ManneWhitney U-test for signif-
icance. Categorical variables were compared using
Chi-square or Fisher’s Exact test as appropriate. (MINITAB
Statistical Software, v 13.32, Minitab Inc., USA). p < 0.05
was taken to indicate statistical significance.Results
Of the 93 patients randomised, 88 patients (47 e RFA (13
men, 34 women), 41 e CS (14 men, 27 women)) underwent
the allocated intervention with a median (interquartile
range [i.q.r]) age of 47 (38e58) and 45 (37e53) respectively
(Fig. 1). There was no follow up loss at a median (i.q.r) of 6
(5e7) and 37 (34e42) days respectively. CEAP Clinical Class
was recorded (C2:C3 RFA 37:9 vs CS 33:7, C4 e one patient
[RFA], C6 e one patient [CS]). The preoperative varicosity
score (Aberdeen Varicose Vein Questionnaire (AVVQ)) was
similar between the groups (median (i.q.r.) score RFA 1.55
(1.03e2.24) vs CS 1.72 (1.29e2.23), 95% confidence interval
(CI) 0.43, 0.19, pZ 0.457, t-test).
Patients who underwent RFA showed no demonstrable
flow in the treated GSV on the duplex scan at first followup. There were seven cases of incomplete stripping in the
CS group showing varying degrees of segmental reflux.
Patients returned to their normal activities (median (i.q.r)
3 (2e5) vs 12.5 (4e21) days, 95% CI 12.00, 2.00,
p < 0.001, ManneWhitney U-test) significantly quicker
following RFA than after CS. Pain (visual analogue score)
during the first week was significantly less following RFA
(median (i.q.r) 1.7 (0.5e4.3) vs 4.00 (2.35e6.05), 95% CI
2.80, 1.00, p < 0.001, ManneWhitney U-test). Ninety
eight percent of those who underwent RFA were willing to
recommend the procedure to others while only 78% would
do so after CS (p < 0.01, Fisher’s exact test). QOL (AVVQ)
improved significantly for the whole group after interven-
tion with a higher, though statistically not significant,
improvement after RFA (mean improvement in QOL score
9.12 vs 8.24, 95% CI 3.64, 1.89, pZ 0.532, t-test).
The total theatre time (between entry into and exit from
theatre suite) was significantly longer for RFA than for CS
(mean (standard deviation [SD]) 83.6 (SD 14.5) vs 55.7
(SD 10.9) min, 95% CI 22.40, 33.41, p < .001, t-test) and was
used in the estimation of theatre costs (Table 2). The actual
procedure time (from commencement, i.e. marking the
course of the GSV with duplex scan in RFA or preparing the
operative field with antiseptic in CS, to completion i.e. the
application of a compression bandage in both cases) was
also significantly longer with RFA (mean (SD) 76.8 (SD 14.5)
vs 47.0 (SD 10.8) min, 95% CI 24.35, 35.32, p < .001, t-test).
The number of phlebectomy incisions above and below the
knee as well as the timing of the phlebectomy incisions in
relation to main part of the operation were comparable
between the two groups and did not impact on the time
differences observed between the procedures.
The mean (SD) hospital cost per patient for RFA was
£1276 (SD £69.6) and for CS was £559 (SD £52.4) (Table 2).
Thus RFA resulted in an additional expenditure of £717.00
(95% CI 690.4, 743.2, t-test) per patient. The difference in
the mean cost per patient incurred by the general practice
(Table 3) and by the patient for undertaking visits to their
general practice for any postoperative problem (£3.40 for
RFA and £7.79 for CS) was small between the two groups as
* Patient preference for conventional surgery (3), patient decided against intervention (3)
Assessed for suitability for trial by duplex ultrasonography (n = 128)
Not suitable for trial (excluded)
(n = 34 limbs in 30 patients)
Anatomical factors           (n = 14)
Pathophysiological factors  (n = 14)
Miscellaneous*          (n = 6)
Suitable but not randomised
(n = 5)
Failure to confirm consent (n = 3) 
Developed thyrotoxicosis  (n = 1) 
Became pregnant      (n = 1)
Suitable and Randomised (n = 93)
Radiofrequency ablation (n = 48)
1 - Did not receive allocated treatment  
    Took name off waiting list (n = 1)
Conventional Surgery (n = 45)
4 - Did not receive allocated treatment 
Took name off waiting list (n = 1)
Developed atrial fibrillation (n = 1) 
New-onset sustained hypertension (n = 1)
Operated on non-trial list (n = 1)
RA (n = 47) CS (n = 41)
Follow up 1 (n = 47)  
Follow up 2 (n = 47)
Follow up 1 (n = 41) 
Follow up 2 (n = 41)
Analysed (n = 41)Analysed (n = 47)
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Figure 1 CONSORT diagram (follow up 1 & 2Z median 6 and 37 days, respectively).
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cases. Costs incurred by the patient for undertaking
non-protocol hospital visits during the postoperative period
(RFA e two visits for 47 patients, CS e four visits for
41 patients) or from the purchase of antibiotics (RFA e
1  1 week course in 47 patients, CS e 3  1 week course in
41 patients) and analgesics were not considered in the final
analysis as the number of such events was considered too
small to make a significant difference to the overall costs.
Patients returned to work (median (i.q.r) 10 (4e13) vs
18.5 (11e28) days, 95% CI 13.00, 3.00, p < 0.001, Manne
Whitney U-test) significantly quicker following RFA thanafter CS. This was taken to be equivalent to a gain of 1
working week for patients undergoing RFA. Majority of
patients (68/88) in the trial were in employment and
worked for a median (i.q.r) of 39 (24e40) h per week at
median (i.q.r) wages of £9.85 (5.52e12.88) per hour with no
significant difference between the two groups. Thus the
cost of employment was estimated to be £384.15 per week.
This would indicate the indirect cost to society for being
unable to return to work for an additional week following
CS. Thus the increased cost of performing RFA was partly
offset by patients returning to work 1 week earlier than
following CS. The resultant difference in the overall cost
Table 4 Comparison of overall costs in employed patients in the trial.
Cost category RFA (£) (mean cost per patient) CS (£) (mean cost per patient)
Hospital cost 1275.90 559.13
General practice cost 9.53 20.12
Patient cost 3.40 7.79
Indirect cost 0.00 384.15
TOTAL 1288.83 971.19
DIFFERENCE £317.64
Additional cost of RFA per
working hour gained (see text)
317.64/39Z £8.14
RFAZ radiofrequency ablation, CSZ conventional surgery.
Costs of Ablation and Surgery for Varicose Veins 109between the two procedures (£317.64) was the additional
cost incurred in performing RFA for a gain of 1 week or 39 h
of employment (Table 4). Thus the cost per every additional
working hour gained following RFA was £8.14 (95% CI 7.47,
8.82, t-test). This may be interpreted as the extra cost
(to the hospital, practice and patient combined) over and
above the cost of conventional varicose vein surgery for
each additional hour of paid employment gained following
radiofrequency ablation treatment.
To obtain a national perspective the hours and earnings
data from trial patients in the above calculation was
substituted by similar data for full time employees in the
UK obtained from employment data maintained by the
Office of National Statistics.14 The median gross weekly
earnings for full time employees in the UK was £431.00 and
the mean weekly paid hours of work for full time employees
in the UK was 39 h. Based on these data, the difference in
the overall costs between the two procedures would be
£270.79 and the extra cost incurred in performing RFA for
each additional hour of full time employment gained would
be £6.94 (95% CI 6.26, 7.62).
Estimation of indirect costs to society in the unemployed
group was difficult as the number of patients was too small
in this category and accurate national estimates of the cost
of unpaid household work for the period of the trial was not
readily available.Discussion
RFA has been shown to be superior to CS in terms of short-
term and medium-term outcomes such as postoperative
pain, return to activities, QOL and patient satisfaction.9,10
One of the key factors that determines the widespread
acceptance of a new intervention is its affordability.
Although long-term outcomes are needed in order to
estimate parameters such as cost-effectiveness of
a particular intervention it is useful to have knowledge of
the actual costs involved in carrying out the procedure as
a starting point in a cost comparison exercise. This is
particularly so if the intervention in question is likely to
bring about a quicker recovery that enables an earlier
return to work, thus potentially off-setting some of the
increased costs of treatment against societal gains. Recent
studies involving RFA have not fully addressed this issue.
This has led many to view RFA as an expensive modality
despite its clinical advantages. One previously reportedrandomised trial that involved 28 patients, performed
partly during the learning experience of the authors, indi-
cated that RFA appeared to be cost-saving for society,
particularly among the employed group, when productivity
loss was included in the cost analysis.8 Our study involved
88 patients with procedures in both arms being performed
by experienced personnel.11 In estimating hospital costs,
we calculated the actual costs involved in carrying out the
procedure rather than using reference costs which are used
by many hospital trusts in the UK for estimation of theatre
and procedural expenses. Reference costs may not yield an
accurate picture as this method results in costs being
averaged out over low and high cost procedures and is likely
to allocate too much to a fairly simple procedure like
varicose vein surgery. Indirect costs to society were
estimated both within the context of the trial and also
based on national employment data from reliable
sources.14
Several factors need to be borne in mind when inter-
preting the results. The method of allocation of overheads
may vary between hospitals. The cost analysis did not
consider the issue of re-treatment of early failures in either
group by the same or different method, as these events did
not occur. Bilateral surgery in the same setting or treat-
ment of incompetent duplicated GSV would not increase
the costs of RFA treatment significantly as the same cath-
eter may be reused for the additional treatment required.
The trial did not involve any bilateral operations and only
one case of duplicated GSV, both trunks of which required
RFA treatment. Costs related to treatment of major
complications like deep vein thrombosis and pulmonary
embolism were also not considered as no such event
occurred during the trial. As these are rare events with
either treatment, the exclusion of these is unlikely to have
significant cost implications. Hours and earnings data
provided by a specialist government department, however
reliable and accurate they may be, may not always be
applicable to a particular local population. For the same
reason they may not be directly applicable to other coun-
tries. In our study, however, the final cost outcome was not
significantly dissimilar in this context between trial
participants and outcome based on national data.
Several factors influence the cost differential between
the treatments. The difference in the hospital costs
between the procedures was mainly due to cost of the RFA
catheter, which contributed to approximately 80% of the
cost difference. The remaining 20% of the difference
110 S. Subramonia, T. Leesresulted from the longer theatre time expended during
RFA treatment. Due to the infrequent incidence of post-
operative problems in either group, the costs incurred by
general practice and patient did not impact heavily on the
cost difference between the treatments. When indirect
costs are considered, the cost differential between the
treatments is also influenced by the nature of employ-
ment of the target population and the time taken to
return to that employment after treatment. For example,
the higher the wages of the target population, the lower
the overall cost of RFA for every gained hour of employ-
ment that was brought about by its use. However the cost
differential between the two treatments is likely to get
smaller in future for several reasons. Firstly as the
procedure becomes more widely accepted the cost of
the catheter is likely to come down. Secondly the inno-
vative design of the newer VNUS ClosureFAST catheter
allows for a ‘segmental ablation’ approach and a signifi-
cantly faster ablation time. Typically a 45-cm vein length
may be ablated in 3e5 min. The median (i.q.r) length of
GSV that was ablated in the trial was 31 cm (29e34.5) and
took a median (i.q.r) of 14 (12.6e15.7) min. Treatment
with this newer RFA catheter could bring about a signifi-
cant reduction in theatre time and hence a reduction in
theatre and overall hospital costs for RFA treatment.
Lastly RFA is routinely performed under tumescent infil-
tration alone in many centres. Within the trial all patients
were operated under a general anaesthetic irrespective of
the procedure. Avoiding an anaesthetic would potentially
reduce theatre time by a further 10e15 min for patients
undergoing RFA and contribute to a further reduction in
theatre costs.
Employment wages may rise in future thus further
narrowing the overall cost differential between the
treatments, although, this factor is unpredictable and
would depend on the target population being treated. The
type of employment may also matter, as in the case of the
self-employed, where there is likely to be an additional
need and incentive for an earlier return to work than those
who are in salaried employment. Only 22% (8/36) and 16%
(5/32) of those employed in the RFA and CS groups
respectively were self-employed. This did not permit
a satisfactory sub-group analysis to be performed. Even if
employment wages are not considered, a reduction in the
cost of the catheter combined with a quicker procedure
performed with newer catheters under tumescent infil-
tration may make the overall costs comparable between
the two treatments.
Future studies on RFA are likely to report on the use of
these instruments with better sophistication and design. It
is however important to remember that CS also improves
QOL and symptoms in the majority of patients with varicose
veins and has been shown to be effective in reducing long-
term recurrence and risk of reoperation.15,16 An analysis
based on long-term anatomical, physiological, patient-
based and clinical outcomes alone would reveal the true
cost-effectiveness of RFA treatment. Until then purchasers
and providers within a healthcare system such as the NHS
in the UK may continue to view radiofrequency ablation
as a more expensive option, despite its significant
early benefits when compared to conventional surgery, in
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